Hikma Prices USD500 Million Five-Year Eurobond (ALLISS)

Wed, 01st Apr 2015 16:43

LONDON (Alliance News) - Hikma Pharmaceuticals PLC Wednesday said it has priced a USD500 million 4.25% eurobond due April 2020, with the proceeds to be used to refinance existing debt and for "general" corporate purposes.

The bond will be listed on the Global Exchange Market of the Irish Stock Exchange.

The joint lead managers were Citi, Barclays, HSBC and National Bank of Abu Dhabi.

Hikma shares closed up 0.1% at 2,131.00 pence in London on Wednesday.

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Related Shares

More News

17 Jun 2024 15:49

London close: Stocks mixed ahead of key UK inflation data

(Sharecast News) - London stocks ended Monday with a mixed performance as renewed concerns over French political uncertainty weighed on investors' min...

17 Jun 2024 09:14

Hikma adds scale to US injectables business with Xellia acquisition

(Alliance News) - Hikma Pharmaceuticals PLC on Monday bolstered its US and injectables business with the purchase of assets from Denmark's Xellia Phar...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

17 Jun 2024 07:42

Hikma boosts injectables business with Xellia assets acquisition

(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty compan...

11 Jun 2024 09:57

LONDON BROKER RATINGS: Morgan Stanley cuts Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:

Latest Share Chat